Joaquin Mateo, Team leader – Principal Investigator at Vall d´Hebron Institute of Oncology (VHIO), shared on LinkedIn:
“Our ZZFIRST trial is out today in Nature Medicine!
An academic randomized phase II trial of Talazoparib + Enzalutamide in high-volume mHNPC integrating spatial transcriptomics on longitudinal tumor biopsies.
Thanks to all patients and funding from DoD/CDMRP and Spanish Association Against Cancer.”
Title: Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
You can also read: TRACE-I: Long-Term Outcomes of PSMA-Guided Salvage Surgery in Recurrent Prostate Cancer
